🚀 Medial Secures Investment on Shark Tank India - Fueling the Future of Professional Social Networking. 🔥
Login

News on Medial

Related News

Sugar.fit posts 77% revenue growth in FY25, narrows losses

EntrackrEntrackr · 16d ago
Sugar.fit posts 77% revenue growth in FY25, narrows losses
Medial

Fintrackr All Stories Sugar.fit posts 77% revenue growth in FY25, narrows losses Sugar.fit, a digital health and diabetes management startup, reported a sharp growth in its operating revenue in the fiscal year ending March 2025, even as losses narrowed marginally amid rising expenses. Priyanshu Kamal 16 Jan 2026 11:29 IST Sugar.fit’s revenue from operations surged 77% to Rs 66.5 crore in FY25 from Rs 37.5 crore in FY24, according to its financial statements sourced from the Registrar of Companies (RoC). Sugar.fit offers a diabetes care program that combines innovative technology with personalized human interventions. Revenue from services was the sole source of income for the company. Including other income of Rs 8.5 crore, Sugar.fit’s total income stood at Rs 75 crore in FY25 from Rs 42 crore a year earlier. On the spending side, advertising and employee-related costs remained the largest cost centres for the company. Expenses stood flat at Rs 34 crore, accounting for 29% of total expenses, while employee benefit expenses rose 18% to Rs 33 crore, forming 28% of overall costs. Cost of materials consumed jumped sharply to Rs 21 crore in FY25 from Rs 0.6 crore in FY24, contributing nearly 18% of total expenditure. Other overheads, including legal and professional charges and miscellaneous expenses, together added over Rs 24 crore during the year. Overall, total expense rose 31.5% to Rs 117 crore in FY25 from Rs 89 crore in FY24. Sugar.fit reduced its losses by 11% to Rs 42 crore in FY25 from Rs 47 crore in FY24. Its ROCE and EBITDA margin stood at -53.66% and -68.27% respectively. On a unit basis, Sugar.fit spent Rs 1.76 to earn a rupee during FY25, an improvement from Rs 2.37 in FY24. Sugar.fit’s cash and bank balances fell sharply to Rs 1 crore as of March 2025 from Rs 5.6 crore in FY24, while current assets stood at Rs 101 crore. According to TheKredible, Sugar.Fit has raised a total of $26 million of funding till date, having MassMutual Ventures and Tanglin Venture as its lead investors. The numbers might look concerning, but there is a reason Sugar.fit is working at it, and that is the sheer size of the market in India. India is diabetes central on Earth, and the data and learnings for Sugar.fit as it keeps expanding its influence is bound to be of value for the firm as well. On a standalone basis, it remains an uphill climb for the firm, as the market has limited paying capacity considering the vast amount of solutions being sold for every pocket. Certainly a firm where investors need to have a longer horizon in mind.

WheelsEye narrows losses by 71% to Rs 39 Cr in FY24

EntrackrEntrackr · 11m ago
WheelsEye narrows losses by 71% to Rs 39 Cr in FY24
Medial

WheelsEye narrows losses by 71% to Rs 39 Cr in FY24 Logistics SaaS firm WheelsEye experienced slower growth since FY22, with revenue growth flattening in FY24. The company reported a marginal 7% increase in revenue for the fiscal year ending March 2024 but successfully reduced its losses by 71% during the same period. WheelsEye’s revenue from operations grew to Rs 218.4 crore in the last fiscal year, from Rs 203.8 crore in FY23, according to its standalone financial statement sourced from the Registrar of Companies (RoC). WheelsEye provides trucking solutions for businesses and software, GPS tracking, and FASTag solutions for truck fleet operators. Revenue from the sale of services (trucking service) increased by 18.9% to Rs 129.6 crore, while revenue from the sale of products (software) grew by 7.85% to Rs 57.7 crore. Income from other sources added another Rs 31 crore. The company made an additional Rs 35 crore from interest income which pushed its total Income to Rs 253 crore in FY24. WheelsEye's largest cost component, employee benefit expenses, dropped by 28.72% to Rs 135 crore. The cost of materials increased slightly by 3.43% to Rs 93.6 crore, while commissions paid decreased by 9.64%, standing at Rs 7.5 crore. Miscellaneous expenses for the last fiscal year amounted to Rs 56.9 crore. In the end, WheelsEye managed to reduce its overall expenses by 17.23%, bringing them down to Rs 293 crore in FY24. This cost optimization contributed to a 71% reduction in net loss, with losses narrowing to Rs 39 crore in FY24. The company also reported improved financial ratios, with its ROCE improving to -44.85% and EBITDA margin rising to -13.76%. Cost efficiency improved as well, with the company spending Rs 1.34 to earn a rupee in FY24. On the asset side, WheelsEye recorded Rs 186 crore in current assets for FY24, which included Rs 142 crore in cash and bank balances. According to the startup data intelligence platform, TheKredible, Wheelseye's parent entity is situated in the USA holding 99.9% of the Indian entity with the name Wheelseye Technology INC. The reduction in losses would be a welcome development at WheelsEye, probably something that has caused the slowdown in growth as well. The effort indicates a push to seek public market access perhaps, even as the firm remains well placed to seek growth again soon. In the past year, seemingly improving efficiency in logistics has led to a slowdown in growth within many firms in the category, something that should correct soon for WheelsEye as well.

Eruditus clocks Rs 3,733 Cr revenue in FY24, narrows losses by 83%

EntrackrEntrackr · 10m ago
Eruditus clocks Rs 3,733 Cr revenue in FY24, narrows losses by 83%
Medial

Eruditus clocks Rs 3,733 Cr revenue in FY24, narrows losses by 83% Global edtech company Eruditus recorded modest year-on-year growth in its operating revenue, crossing the Rs 3,700 crore ($448 million) mark in the fiscal year ending June 2024. The Mumbai-based firm narrowed its losses by over 83% during the same period. Compared to FY23, the firm’s operating scale grew by 12% to Rs 3,733 crore, according to its annual financial statement sourced from Singapore. Eruditus follows a financial year that runs from July to June. The firm appears to be ahead of the leading edtechs, with revenue nearly 1.8 times that of PhysicsWallah and more than double that of upGrad. PhysicsWallah reported Rs 2,015 crore revenue in FY24 whereas upGrad registered Rs 1,487 crore revenue in the same period. Eruditus offers education across more than 80 countries to over a million learners. It partners with over 80 universities across the United States, Europe, Latin America, Southeast Asia, India, and China. The firm didn’t offer revenue break-up across geographies. The company deferred recognition of Rs 800 crore ($96 million) in collected revenue to the last fiscal year (FY25). Eruditus made progress in controlling its expenses as its marketing expenses dipped 18.85% year-on-year to Rs 1,007 crore in FY24 from Rs 1,241 crore in FY23. Other operating expenses were down by 32.16% year-on-year to Rs 1,045 crore in FY24 from Rs 1,541 crore in FY23. The cost optimizations led to a sharp improvement in the company’s bottom line. Eruditus narrowed its adjusted EBITDA losses by 83.45% to Rs 69 crore ($8.3 million) in FY24 from Rs 417 crore ($50 million) in FY23. With backing from investors such as TPG, the Chan Zuckerberg Initiative, SoftBank Vision Fund 2, Prosus Ventures, Accel, and Peak XV, Eruditus has the capital reserve to expand its presence and offerings across markets. In October 2024, it raised $150 million in the second-largest edtech deal of the year, after PhysicsWallah’s $210 million funding. With revenue approaching $500 million and an 83% reduction in losses, the company shows a path toward sustainable growth in the edtech industry. Heading into FY25 with deferred revenue, Eruditus is on track to achieve profitability while building on its revenue base.

Portea posts Rs 160 Cr revenue in FY25; narrows losses

EntrackrEntrackr · 16d ago
Portea posts Rs 160 Cr revenue in FY25; narrows losses
Medial

Portea, a Bengaluru-based home healthcare services provider, has halved its losses during the fiscal year ended March 2025. The improvement came on the back of steady revenue growth with controlled expenses in the period. Portea’s revenue from operations grew by 15% to Rs 160 crore in FY25 from Rs 139 crore in FY24, according to its consolidated financial statements sourced from the Registrar of Companies (RoC). Portea offers a range of at-home healthcare services such as nursing, physiotherapy, medical equipment rentals, attendant care, lab tests, consultations, and specialised care. Revenue from these services remained the largest contributor, accounting for 59% of operating income, which rose by 16% year-on-year to Rs 95 crore in FY25. Meanwhile, revenue from product sales, including oxygen concentrators, BiPAP machines, and nebulisers, grew 14% to Rs 56 crore in FY25. Looking at the expenses, the employee benefit cost declined by 4.5% to Rs 52.5 crore in FY25. Its consultancy expenses rose 7% to Rs 44 crore. Meanwhile, the cost of materials increased 21% to Rs 52 crore, and expenses rose 25% to Rs 7.5 crore during the fiscal year. Other overheads, including legal and professional charges, and finance costs, added over Rs 30 crore to the total expense. Overall, Portea kept its total expenses flat at Rs 179 crore in FY25. With revenue rising and costs remaining stable, Portea managed to cut its loss by 49% to Rs 19 crore in FY25 from Rs 37 crore in FY24. Its ROCE and EBITDA margins stood at -40.54% and -6.88%, respectively. On a unit basis, Portea spent Rs 1.12 to earn a rupee during the fiscal year, improving from Rs 1.29 in FY24. The company reported cash and bank balances of Rs 1 crore, while its current assets stood at Rs 68 crore as of March 2025. According to TheKredible, Portea has raised nearly $123 million in funding to date, having Accel and Ventureast as its lead investors. It is worth noting that Portea received SEBI’s approval in 2023 to launch a Rs 1,000 crore initial public offering, but the company has since not taken any further steps to move ahead with the listing.

Vahdam Teas narrows losses by 68% to Rs 18 Cr in FY24

EntrackrEntrackr · 1y ago
Vahdam Teas narrows losses by 68% to Rs 18 Cr in FY24
Medial

Direct-to-consumer (D2C) tea brand Vahdam experienced modest double-digit growth during the last fiscal year. Despite this, the company significantly improved its unit economics by reducing losses by 68%, bringing them down to under Rs 20 crore. Vahdam Teas’ revenue from operations grew by 10.6% to Rs 225.2 crore in FY24 from Rs 203.6 crore in FY23, as per its consolidated financial statement filed with the Registrar of Companies (RoC). Vahdam Teas directly sources premium tea and spices from farms and estates across India. It sells these products to customers both locally and internationally, including in the US, Canada, and Europe, through its own website and online marketplaces. Product sales contributed 99% of Vahdam's operating revenue. Geographically, the USA remained the primary revenue driver, accounting for 68.5% of the total operating revenue, with a 12% growth to Rs 154.2 crore. Revenue from India grew by 18% to Rs 14.84 crore, while Europe and the rest of the world contributed Rs 37.4 crore and Rs 18.8 crore, respectively, showing steady growth of 5-6%. The company made an additional Rs 10 crore from non-operating revenue, which pushed its total revenue to Rs 235 crore in FY24. On the expense side, Vahdam curtailed major costs. Advertising expenses, one of its significant outlays, were reduced by 18.9% to Rs 50 crore in FY24. Freight and forwarding charges also declined by 7% to Rs 68 crore. Meanwhile, the cost of materials remained stable at Rs 47 crore, and employee benefit expenses rose by 18.4% to Rs 29 crore. Other overheads stood at Rs 58.9 crore. Overall, the company's total expenses fell by 4.7% to Rs 253 crore in FY24, from Rs 265.5 crore in FY23. The Delhi based firm’s losses declined by 68% to Rs 17.7 crore in FY24 from Rs 55 crore in FY23. Its ROCE and EBITDA margin stood at -13.2% and -4.26%, respectively. Its expense-to-earning ratio stood at Rs 1.12. As of March 2024, the firm reported Rs 142 crore of current assets including Rs 83 crore of cash and bank balance. According to TheKredible, Vahdam Teas has raised a total of $39 million in funding till date, having Fireside Ventures, Sixth Sense Ventures and IIFL Asset Management as its lead investors.

Medibuddy posts Rs 725 Cr revenue in FY25, narrows losses by 37%

EntrackrEntrackr · 1m ago
Medibuddy posts Rs 725 Cr revenue in FY25, narrows losses by 37%
Medial

MediBuddy posts Rs 725 Cr revenue in FY25, narrows losses by 37% Following more than 2X growth in the fiscal year ending March 2024, digital healthcare platform MediBuddy reported modest growth in its operating scale in FY25, while managing to narrow its losses by 37% during the period. MediBuddy's operating revenue grew 12.3% year-on-year to Rs 724.6 crore in FY25 from Rs 645.4 crore in the previous fiscal year (FY24), according to the company's annual financial statements filed with the Registrar of Companies (RoC). MediBuddy, a digital healthcare platform, provides online and offline medical consultations, medicine delivery, lab tests, surgeries, and insurance services, with revenue from these forming the primary source of income at Rs 722 crore, supplemented by Rs 2.5 crore from other operating sources. The company also earned Rs 18.42 crore from non-operating sources, including interest on fixed deposits and current investments, written-off liabilities, and other miscellaneous income, pushing its total income to Rs 743 crore in FY25. On expenses, the cost of materials was the largest at 38% of total expenses, standing at Rs 333 crore. Employee benefits expenses rose marginally by 8% to Rs 176.8 crore, including Rs 6 crore in ESOP expenses. Sales payout expenses, including commissions to selling agents, fell 7% to Rs 155.47 crore. The company spent Rs 42.5 crore on safety and security and Rs 32.5 crore on IT. Other overheads, including legal and professional fees, advertising, depreciation and amortization, and finance costs, amounted to Rs 138.7 crore. Overall expenses for the Bengaluru-based firm remained flat at Rs 879 crore, with controlled expenditure and a 12% rise in revenue helping to narrow losses by 37% to Rs 137 crore from Rs 215.7 crore in FY24. On a unit basis, MediBuddy spent Rs 1.21 to earn one rupee of operating revenue, with its EBITDA margin improving to -14.19% in FY25 from -25.67% in the previous year, resulting in an EBITDA loss of Rs 103 crore. As of March 2024, MediBuddy's current assets were Rs 395.2 crore, including cash and bank balances of Rs 80 crore. MediBuddy has raised over $190 million to date, last raising $18 million in August 2023 from existing investors Quadria Capital, Lightrock, and TEAMFund. It competes with companies including Pristyn Care-owned Lybrate, Practo, and mFine Tata 1mg.

Download the medial app to read full posts, comements and news.